Melanoma | Karl D Lewis, MD

published 5 months ago by Dr Neil Love

Melanoma Update, Issue 1, 2021 — Part 2: Our interview with Dr Lewis highlights the following topics as well as cases from his practice: Approved and investigational strategies for patients with metastatic melanoma (0:00) Case: A man in his late 70s with metastatic melanoma and an NRAS mutation who receives stereotactic radiosurgery and single-agent pembrolizumab (27:41) Case: A woman in her early 60s with metastatic melanoma and a BRAF V600 mutation who receives encorafenib and binimetinib as first-line therapy (31:04) Case: A man in his early 50s with metastatic melanoma and a BRAF V600 mutation (33:45) Therapeutic options for patients with metastatic melanoma in the first-line setting (37:45) Results and clinical implications of the Phase III IMspire150 trial of atezolizumab in combination with cobimetinib and vemurafenib for previously untreated advanced melanoma with a BRAF V600 mutation (44:25) Mechanism of action and activity of bempegaldesleukin in combination with an immune checkpoint inhibitor; rationale for the investigation of TILs for metastatic melanoma (50:16) Emerging data with pembrolizumab/lenvatinib for patients with advanced melanoma whose disease has progressed on an anti-PD-1/PD-L1 antibody (56:06) Choice of therapy for patients with BRAF wild-type metastatic melanoma (59:43) Activity and tolerability of ipilimumab/nivolumab for advanced melanoma (1:03:48) Selection and sequencing of therapy for patients with metastatic melanoma and BRAF mutations (1:08:12) Therapeutic approach to metastatic melanoma with a BRAF mutation and a high disease burden (1:11:36) Efficacy and side-effect profile of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) for metastatic melanoma with a BRAF mutation (1:15:39) CME information and select publications

more episodes from Research To Practice | Oncology Videos